Advances on drug therapy for KRASG12C-mutant non-small-cell lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41529383/
Lung cancer has an extremely high mortality rate among malignant tumors, posing a significant threat to human health Among all lung cancer cases, non-small cell lung cancer (NSCLC) accounts for...
Review summarizes breakthroughs in KRASG12C-mutant NSCLC, highlighting adagrasib and sotorasib efficacy, resistance mechanisms, and emerging combination strategies to address tumor heterogeneity and improve clinical outcomes.
Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41511559/
Leptomeningeal metastasis in patients with Epidermal Growth Factor Receptor-mutant non-small cell lung cancer carries a dismal prognosis and is associated with profound neurological morbidity. Historically, therapeutic efficacy has been severely...
Review summarizes evolving management of leptomeningeal metastasis in EGFR-mutant NSCLC, highlighting improved CNS-penetrant TKIs, adjunct radiotherapy and intrathecal therapies, diagnostic advances, persistent resistance challenges, and future research directions.
Successful treatment of lung squamous cell carcinoma with envafolimab, a PD-L1 inhibitor combined with chemotherapy: a case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41510120/
This case shows the potential efficacy of envafolimab-based combination therapy in achieving a clinically significant and durable response for a patient with metastatic squamous NSCLC (sq-NSCLC) who showed disease progression...
This case report describes durable tumor regression with envafolimab plus chemotherapy in metastatic squamous NSCLC after pembrolizumab failure, highlighting potential efficacy of subcutaneous PD-L1 inhibition in resistant disease.
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41428976/
These results support the antitumor activity and safety of seribantumab in patients with advanced solid tumors harboring NRG1 fusions.
Phase II CRESTONE study shows seribantumab demonstrated meaningful antitumor activity and manageable safety in advanced solid tumors with rare NRG1 fusions, supporting HER3-targeted therapy as a precision treatment option.
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41477303/
Alectinib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been widely used as first-line (1L) treatment of advanced ALK+ non-small cell lung cancer (NSCLC) ever...
Case report describes semaglutide use for alectinib-induced weight gain in ALK-positive NSCLC, demonstrating effective weight loss but complicated by gallstone pancreatitis, highlighting benefits and risks of GLP-1 agonists.